Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

enasidenib

Novartis building

Novartis gets speedy FDA review for midostaurin

Leukaemia treatment could become first targeted therapy for 25 years

- PMLiVE

NICE set to knock-back Amgen’s myeloma treatment Kyprolis

Cites uncertainty in clinical and cost-effectiveness analyses

Celgene building

Celgene engages IBM Watson for patient safety work

Aims to improve its pharmacovigilance methods with a new cloud-based platform

Celgene plans real-world study using Apple’s ResearchKit

Will develop an iPhone app to assess burden of chronic anaemia

Celgene building

Celgene plans real-world study using Apple’s ResearchKit

Will develop an iPhone app to assess burden of chronic anaemia

- PMLiVE

Shire wins EU licence for pancreatic cancer drug Onivyde

Combination treatment is the first approved for this patient population

- PMLiVE

PMEA 2016 finalists announced

AbbVie, Bayer, Celgene and Novartis are up for the prestigious Company of the Year

Deal Watch September 2016

Abbott, Allergan, Celgene, Moderna, Pfizer and Takeda feature in this month's pharma deals round-up

Roche Basel Switzerland

AbbVie and Roche’s leukaemia drug venetoclax nears EU market

CHMP grants blood cancer treatment Venclyxto a conditional green light

Celgene building

Celgene bolsters blood cancer portfolio with $600m EngMab buy

Consolidates position as top company in current multiple myeloma market

- PMLiVE

AbbVie’s venetoclax set for early access in UK

Drug for CLL patients included in EAMS by MHRA

- PMLiVE

Rare blood cancer therapy Oncaspar gets NICE green light

Baxalta’s acute lymphoblastic leukaemia treatment recommended for NHS use

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links